key: cord-0934600-33cbs60c
authors: Agouridis, Aris P.; Pagkali, Antonia; Zintzaras, Elias; Rizos, Evangelos C.; Ntzani, Evangelia E.
title: High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?
date: 2021-08-24
journal: Atherosclerosis plus
DOI: 10.1016/j.athplu.2021.08.007
sha: 6b9aef537a780cf83231829566aee84826c0bf1b
doc_id: 934600
cord_uid: 33cbs60c

Background and aims To systematically address all the relevant evidence of the association between high-density lipoprotein cholesterol (HDL-C) and COVID-19 infection. Methods We searched PubMed, PubMed Central and medRxiv databases (up to May 2021) for studies related to HDL-C and COVID-19 infection. A qualitative synthesis of published prospective and retrospective studies for the role of low HDL-C levels on COVID-19 infection severity was performed. Results Thirty-three studies (6 prospective, 27 retrospective) including 11,918 COVID-19 patients were eligible for the systematic review. Twelve studies compared HDL-C levels on admission in COVID-19 patients with healthy controls. In these 12 studies, COVID-19 patients had significantly lower HDL-C levels on admission compared with that of healthy controls. Twenty-eight studies observed the HDL-C levels among COVID-19 diagnosed patients, to establish the role of low HDL-C values in the prognosis of the infection. Twenty-four studies showed a correlation between low HDL-C levels with disease severity, while only 4 studies showed no association. Conclusions Low HDL-C levels should be added in the list of the others well-known risk factors for COVID-19 severity.

The coronavirus disease 2019 is caused by a novel strain of coronavirus, named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1] . The first case of a patient infected by the SARS-CoV-2, causing viral pneumonia, was presented in December 2019 in the city of Wuhan in China [2] . The World Health Organization (WHO) declared coronavirus disease a global pandemic in March 2020 and an international public health emergency issue. As of May [3] .

The estimated mortality rate for COVID-19 is about 2.3% [4] among the confirmed cases. Until recently, studies have demonstrated that disease's worse prognosis is associated with patients' older age and comorbidity status [5] . However, studies have brought to the surface that other factors, including patients' laboratory data, can play an additional predictive role in COVID-19 prognosis [5] [6] [7] . In particular, low absolute count of lymphocytes, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer levels, lactate dehydrogenase (LDH), troponin, ferritin and creatinine phosphokinase (CK) at onset are associated with disease progression and poor outcomes [5, 6] .

The majority of patients with mild to moderate disease have a better prognosis, than those who are classified as severe to critical cases, concerning mortality rates [8] . Since the COVID-19 has nowadays become a global threat to public health, an urge has been generated to interpret early patients' laboratory values and to identify those with severe disease and a poorer prognosis, in order to facilitate the appropriate supportive care and improve the recovery rate. As such, cheap and easy to perform biomarkers like lipid levels could be useful in clinical practice, especially in those settings where more sophisticated or expensive biomarkers cannot be performed, like in underdeveloped countries with poor resources. So far, little is known about the association between disease severity and lipid levels. Critical illness is well known to J o u r n a l P r e -p r o o f 4 be accompanied by low levels of total cholesterol (TCHOL) and apolipoprotein B [9] . These alterations are attributed to increased production of certain cytokines and may suggest worse prognosis and increased mortality. Low high-density lipoprotein cholesterol (HDL-C) levels may be seen in several infectious diseases [9] . Of note, HDL-C levels can get rapidly decreased in septic conditions [10, 11] .

Our aim is to assess the role of HDL-C levels on COVID-19 infection in a systematic way.

J o u r n a l P r e -p r o o f

We searched PubMed, PubMed Central and medRxiv databases up to 18 th of May 2021 using the keywords (HDL-Cholesterol OR high-density lipoprotein cholesterol OR HDL) AND (COVID-19 OR SARS-COV-2 OR Coronavirus).

We performed a qualitative synthesis of published prospective or retrospective studies to evaluate whether low HDL-C levels are associated with COVID-19 infection severity.

Studies were independently and thoroughly examined by two investigators (APA, AP) and studies' characteristics were extracted. Any discrepancy between the reviewers was resolved by consensus. For the review of our analysis, data extraction was performed with adherence to Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA model, Figure 1) [12]. Original articles are included in the present systematic review. We additionally assessed the references of these articles, as well as reviews on the topic to identify for any missed relevant studies.

J o u r n a l P r e -p r o o f

Thirty-three studies, with a total of 11,918 COVID-19 patients, were included in our systematic review (Table 1) . Twenty-three of them were retrieved from PubMed database, 8 from medRxiv database, 1 from PubMed Central and 1 from Social Science Research Network (SSRN). The studies retrieved from medRxiv and SSRN are preprints and have not been peerreviewed. Among all 33 studies, 27 were retrospective, while only 6 were conducted prospectively. Twelve studies compared the HDL-C levels on admission in COVID-19 patients with controls (Table 2 ). In all these 12 studies, COVID-19 patients had significantly lower HDL-C levels on admission compared with that of healthy controls. Twenty-eight studies observed the HDL-C levels among COVID-19 diagnosed patients, to establish any correlation between HDL-C values and prognosis of the disease (Table 3 ). Among them, 23 studies showed a negative correlation between HDL-C levels and disease severity, while only 1 study showed a positive correlation, and 4 studies showed no association.

In an observational cohort study, the association of lipid profile with disease severity and mortality in 99 COVID-19 patients was assessed [13] . The authors found that HDL-C and apoA1 levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels (p < 0.0001). Furthermore Upon admission, HDL-C levels were low [27.1 mg/dL (19.3-34.8)], but throughout disease improvement, HDL-C levels during the 28-study period increased compared with admission (p = 0.024). The HDL levels also returned within their normal reference levels in survivors' group.

Importantly however, there was no relationship between HDL-C and LDL-C values with mortality (log-rank p = 0.554 and p = 0.083, respectively). In addition, no differences in HDL-C and LDL-C levels between survivors and non-survivors were observed over time [14] .

In a monocentric study conducted in a surgical intensive care unit (ICU) in 

In a population-based study from Hong Kong, among 268 COVID-19 patients, 43 met the primary outcome (composite intensive care unit admission, need for intubation or death) [16] . Those patients had significantly lower HDL-C levels [ 9-192.7) ], (p < 0.001). The authors concluded that severe outcome was associated with lower HDL-C and higher triglyceride levels [17] .

A recent study, using data from the UK Biobank, investigated the relationship between severity of COVID-19 and HDL-C levels [18] . Among included cases, 968 COVID-19 patients had significantly lower HDL-C levels (50 ± 18 mg/dL) compared with that of 3,087 unmatched hospital-based controls C (53 ± 19 mg/dL), (p < 0.001). Of importance, a 10 mg/dl increase in serum HDL-C levels was associated with significantly (p = 0.0004) reduced risk of SARS- patients, 132 non-severe COVID-19 patients and 76 healthy individuals as control group [20] .

Serum HDL-C levels in COVID-19 group (39.5 ± 10.8 mg/dL) were significantly lower compared with the control group (58.8 ± 21.3 mg/dL), (p < 0.05). Notably, HDL-C levels in patients with severe COVID-19 (32.1 ± 64.6 mg/dL) were significantly lower than that in nonsevere COVID-19 patients (44.5 ±10.5 mg/dL), (p < 0.05). The authors concluded that HDL-C represents a poor prognostic factor in COVID-19 disease severity [20] .

In another retrospective study conducted in Turkey, the atherogenic index of plasma (AIP), calculated as the base 10 logarithm of the triglyceride to HDL-C ratio, was found to consist an early biomarker to predict pneumonia, intubation and intensive care need in 139 COVID-19 patients [21] . Among them, 26 patients died. The AIP in the deceased group was significantly higher compared with that in the survivor group (p < 0.001). Of note, the deceased group had more patients with hypertension (p = 0.006), diabetes mellitus (p = 0.002), cardiovascular diseases (p = 0.001) and chronic renal failure (p = 0.003) compared with the survivor group [21] . Regarding lipid profile, TCHOL, HDL-C and LDL-C levels were lower (p = 0.004, p < 0.001, p < 0.001, respectively) and triglyceride levels were higher (p < 0.001) in deceased patients when compared with survivors. More specific, HDL-C levels in deceased patients were 28.5 (21.5 -32.0) mg/dL while in survivors were significantly higher 44.0 (32.5 -77.0) mg/dL, (p < 0.001) [21] .

Among 107 COVID-19 inpatients that were included in a retrospective analysis, 82 survived while 25 died [22] . Although no difference was observed in HDL-C levels on admission between survivors and non-survivors (36.7 vs 33.3 mg/dL, p = 0.323), on their last tests this difference became profound (41.4 vs 30.6 mg/dL, p = 0.006) [22] .

A retrospective case-control study conducted in Iran included 250 COVID-19 patients [23] . No significant difference on HDL-C levels was observed between 103 deceased and 147 [24] . In this retrospective study, the authors reported that HDL-C levels were significantly higher in the 74 severe cases (39.8 ± 18.9 mg/dL) compared J o u r n a l P r e -p r o o f with 174 common cases on admission (33.3 ± 12.0 mg/dL) (p < 0.001). Notably, among 68 severe cases, HDL-C levels were lower in 33 patients who needed hospitalization for more than 29 days compared with the 35 severe cases that needed hospitalization for less than 29 days (p < 0.05). Regarding LDL-C, common cases exhibited lower levels (85.1 ± 35.2 mg/dL) compared with that of severe cases (77.0 ± 29.0 mg/dL), (p = 0.024). The authors concluded that an increase in LDL-C and HDL-C during hospitalization of severe COVID-19 cases seems to predict disease recovery [24] .

Fan et al. study included 21 COVID-19 infected patients [25] . Comparison was made between them and a control group, which included 31 healthy non-COVID-19 individuals.

While HDL-C in healthy subjects ranged among normal levels [ In another study, a total of 98 COVID-19 positive patients were enrolled and divided to ICU/non-ICU and survivors/non-survivors groups [26] . Disease severity was associated with 

Similar results were shown in the 8 studies that were retrieved from medRxiv database [36] [37] [38] [39] [40] [41] [42] [43] , the 1 from PubMed Central [44] and the 1 from Social Science Research Network (SSRN) [45] . The studies retrieved from medRxiv and SSRN are preprints and have not been peer-reviewed. The results of the above studies are summarized in Tables 1, 2 

This systematic review focuses on the association of HDL-C with COVID-19 infection.

Our results suggest that low HDL-C levels consist a poor prognostic factor for COVID-19 severity.

Several well-known poor prognostic factors for COVID-19 infection, such as low absolute lymphocyte count and high levels of C-reactive protein (CRP), D-dimers, troponin, lactate dehydrogenase (LDH), creatine kinase (CK), and ferritin have been previously reported.

Additionally, more sophisticated biomarkers such as several interleukin levels are of prognostic value [46] . We now present the evidence regarding HDL-C levels in a systematic way, since it represents a biomarker easy to perform across the universe, is well standardized and is cheap compared to many of the previously reported biomarkers, which are not easy to perform especially in poor resource settings.

A recent analysis that used data of 317,306 (171,466 women) participants from the UK Biobank showed that high HDL-C levels were associated with a lower risk of hospitalisation due to COVID-19 infection [47] . Similarly, data from 9,005 UK Biobank participants (1508 positive for COVID-19 infection) showed that elevated plasma HDL-C, as well as elevated ApoA1 levels, were associated with a reduced odds of testing positive for SARS-CoV-2 (OR = 0.845, 95% CI = 0.788 -0.907) [48] . Moreover, in another genetic and exposure analysis that included 7,362 subjects from the UK Biobank (1,485 positive for COVID-19 infection) COVID-19 participants had lower HDL-C levels compared with non-COVID-19 participants [49] . In addition, a significant correlation between HDL and genetic factors (single-nucleotide polymorphisms) was observed [49] .

Low HDL-C levels may be attributed to inherited disorders or secondary causes [9] .

Inherited forms include familial hypoalphalipoproteinemia, Tangier disease or Lecithine:cholesterol acylotransferase (LCAT) deficiency, while secondary causes of low J o u r n a l P r e -p r o o f HDL-C levels include cigarette smoking, obesity, low-fat diet, hyperthyroidism, diabetes, chronic kidney disease, malignancies, paraproteinemias, several drugs and infections [9, 50] .

Regarding infections, low HDL-C levels may be attributed to several infectious diseases, such as visceral leishmaniasis [51] , severe leptospirosis [52] , acute brucellosis [53] , pulmonary tuberculosis [54] , tick-borne encephalitis [55] , as wells as chronic hepatitis B and C [56, 57] .

Furthermore, HDL-C levels can get rapidly decreased in septic conditions [10, 11].

The mechanisms by which COVID-19 infection reduces HDL-C levels, as well as HDL functionality are not clearly defined. It seems that the "cytokine storm" underlying COVID-19 infection produces immune-mediated inflammatory dyslipoproteinemia, leading to low HDL-C levels [58] . In particular, elevated levels of interleukin-6 and other cytokines in COVID-19 infection may inhibit the apolipoprotein AI synthesis, which results to decreased HDL-C levels.

In addition, the "cytokine storm" increases the activity of secretory phospholipase A2 (sPLA2) and endothelial cell lipase, enzymes that metabolize key HDL constituents and eventually leading to decreased HDL-C levels [59] . Furthermore, low HDL-C levels can be partially explained by the increased hepatic production of serum amyloid A (SAA) levels during inflammation [58] . SAA can displace apolipoprotein AI and AII from the HDL surface to produce an SAA-enriched HDL, which is catabolized at a faster rate compared to the normal HDL particle. Moreover, various cytokines during inflammation, decrease the activity of lipoprotein lipase (LPL), thus reducing peripheral clearance of very low density lipoproteins (VLDLs) [59] . This results in elevation of triglycerides and triglyceride-rich lipoproteins (such as VLDLs) leading to an increase of triglyceride content within HDL particles. The triglyceriderich HDLs are then hydrolysed by the hepatic lipase and the LPL producing small HDLs. Small HDLs lead to increased breakdown of HDL, resulting in decreased HDL-C levels [59] . Of importance, initial COVID-19 data have even indicated that healthy infected individuals display abnormal liver function tests, suggesting a possible direct implication of SARS-CoV-2 in liver J o u r n a l P r e -p r o o f damage [30] . As a result, liver dysfunction itself is associated with low to very low HDL-C levels, which, according to recent data, is strongly associated with mortality [60] . The above findings suggest that HDL protein composition and function are altered in COVID-19 patients, implying that not only quantity but also quality of HDL matters [61, 62] . Notably, shotgun proteomics was performed on HDL fractions and their endothelial protective effect was tested on human umbilical vein endothelial cells [15] . Study results showed that HDL particles from ICU severe COVID-19 patients were characterized by quantitative and qualitative abnormalities compared to those isolated from healthy subjects [15] . Those dysfunctional HDL particles were characterized by a loss of protective effect towards endothelial cells in inflammatory conditions [63] . These findings could play a role also in the treatment of the acute phase of COVID-19 infection [64] . Proposed interventions to either improve HDL functionality, such as increasing LCAT activity mentioned above, or replenishment with functional HDL or relevant apolipoproteins, such as ApoA-I mimetic peptides could be beneficial for the management of SARSCoV-2 related complications [58] . Interestingly, a recent study in 115 COVID-19 patients with SARS-COV-2 nucleic acid positive time exceeding 14 days showed that HDL-C reduction was an independent risk factor of the prolonged nucleic acid turning negative time, suggesting that HDL-C plays a role in virus clearance from the human body [65] . Importantly, HDLs have been shown to be a part of the innate immune system [59] .

HDL can buffer toxic materials derived from infection and inflammation by moderating the inflammatory burst. We suggest that this protective mechanism is minimized with the low HDL-C concentrations we find in COVID-19. Hence, low HDL levels are not only a side effect of inflammation and infection, but also contribute to poor disease progression.

Several limitations are present in this systematic review. Most of the studies are of low methodological quality, with the majority being retrospective and a significant percentage of J o u r n a l P r e -p r o o f them been reported without peer review process. Small sample sizes, no clear assessing for confounders and heterogeneous reporting further limit the quality of the evidence base. Finally, we were not able to perform a meta-analysis as metrics such as OR were not reported in the vast majority of the studies. However, we strongly suggest that COVID-19 patients may benefit from monitoring more closely their lipid profile.

The authors declare no conflict of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Agouridis AP conceptualized and designed the study, participated in data acquisition, extraction and interpretation, prepared tables, wrote and drafted the initial manuscript and approved the final manuscript as submitted; Pagkali A and Rizos EC participated in data analysis and interpretation, reviewed and revised the manuscript and approved the final manuscript as submitted; Zintzaras E and Ntzani EE verified the analytical methods, performed all the relevant calculations and technical details of the systematic review, reviewed and revised the initial manuscript and approved the final manuscript as submitted; J o u r n a l P r e -p r o o f 

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Coronavirus Disease 2019 in China

World Health Organization. Coronavirus disease (COVID-19) outbreak

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72314

Cases From the Chinese Center for Disease Control and Prevention

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity

Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong

Low HDL and high triglycerides predict COVID-19 severity

Association of serum HDLcholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection

Lipid metabolism changes in patients with severe COVID-19

The clinical value of high-density lipoprotein in the evaluation of new coronavirus pneumonia

The atherogenic index of plasma as a predictor of mortality in patients with COVID-19

Temporal changes in laboratory markers of survivors and non-survivors of adult inpatients with COVID-19

An investigation of risk factors of in-hospital death due to COVID-19: a case-control study in Rasht, Iran

Alteration of lipid profile and value of lipids in the prediction of the length of hospital stay in COVID-19 pneumonia patients

Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019

Triglyceride to High-Density Lipoprotein Cholesterol Ratio is an Important Determinant of Cardiovascular Risk and Poor Prognosis in Coronavirus Disease-19: A Retrospective Case Series Study

Hypolipidemia is associated with the severity of COVID-19

Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection

Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases

Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study

Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19

Effect of COVID-19 on Lipid Profile and its Correlation with Acute Phase Reactants

Serum lipid profile changes and their clinical diagnostic significance in COVID-19 Mexican Patients

Cholesterol Metabolism-Impacts on SARS-CoV-2 Infection Prognosis

Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19

SARS-CoV-2 Antibody Prevalence and Association with Routine Laboratory Values in a Life Insurance Applicant Population

Potential Factors for Prediction of Disease Severity of COVID-19 Patients

Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a doublecenter observational study

High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients

Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou

Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review

High density lipoprotein cholesterol and risk of subsequent COVID-19 hospitalisation: the UK Biobank study. medRxiv

Baseline Cardiometabolic Profiles and SARS-CoV-2 Risk in the UK Biobank

Association analysis framework of genetic and exposure risks for COVID-19 in middle-aged and elderly adults

Tangier disease four decades of research: a reflection of the importance of HDL

New-onset extremely low levels of high-density lipoprotein cholesterol

Serum lipid profile in patients with severe leptospirosis

Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella

Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis

Characteristics of lipids imbalance in patients with tick-borne encephalitis

Chronic hepatitis B virus infection and dyslipidemia

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up

COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches

Lipid testing in infectious diseases: possible role in diagnosis and prognosis

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure

Dysfunctional high-density lipoprotein: not only quantity but first of all quality

High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality

Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

Should raising high-density lipoprotein cholesterol be a matter of debate?

High-density lipoprotein cholesterol as a factor affecting virus clearance in covid-19 patients

2020 (32567003) China Retrospective

2020 (32892746) China Retrospective

2020 (32636061) China Retrospective

China Retrospective

COVID-19: coronavirus disease 2019; HDL-C: High-Density Lipoprotein Cholesterol; ICU: Intensive Care Unit